Niacin improves renal lipid metabolism and slows progression in chronic kidney disease

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 1, 2010, Pages 6-15

  Cho, Kyu hyang ^a,b   Kim, Hyun ju ^a   Kamanna, Vaijinath S ^c   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Yeungnam University   (South Korea)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Anti inflammatory antioxidant agent; Atherosclerosis; Hypertension; Inflammation; Oxidative stress; Proteinuria; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER G1; BINDING PROTEIN; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; CD36 ANTIGEN; FATTY ACID BINDING PROTEIN; LIVER X RECEPTOR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; HYPERTENSION; KIDNEY METABOLISM; KIDNEY TUBULE DISORDER; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

ANIMALS; ANTIGENS, CD36; ATP-BINDING CASSETTE TRANSPORTERS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LIPIDS; MALE; NIACIN; ORPHAN NUCLEAR RECEPTORS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SCAVENGER RECEPTORS, CLASS B; VITAMIN B COMPLEX;

RATTUS;

EID: 71749115788     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.10.009     Document Type: Article

References (70)

1. Remuzzi G., Beniqni A., and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116 (2006) 228-296
2. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. 290 (2006) F262-F272
3. Vaziri N.D., and Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial. Int. 10 (2006) 1-7
4. Moradi H., Pahl M.V., Elahimehr R., and Vaziri N.D. Impaired antioxidant activity of HDL in chronic kidney disease. Transl. Res. 153 (2009) 77-85
5. Vaziri N.D., Moradi H., Pahl M.V., Fogelman A.M., and Navab M. ApoA-1 mimetic peptide enhances HDL anti-inflammatory and lowers LDL pro-inflammatory properties in uremic plasma. Kidney Int. 76 (2009) 437-444
6. Shoji T., Nishizawa Y., Nishitani H., Billheimer J.T., and Sturley S.L. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 41 (1992) 1653-1661
7. Guarnieri G.F., Moracchiello M., Campanacci L., et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int. 13 (1978) S26-S30
8. Mcleod R., Reeve C.E., and Frohlich J. Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int. 25 (1984) 683-688
9. Liang K., and Vaziri N.D. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. Am. J. Physiol., Endocrinol. Metab. 283 (2002) E676-E681
10. Vaziri N.D., and Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am. J./ Physiol., Renal Physiol. 287 (2004) F1038-1043
11. Abrass C.K. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am. J. Nephrol. 24 (2004) 46-53
12. Dalrymple L.S., and Kaysen G.A. The effect of lipoproteins on the development and progression of renal disease. Am. J. Nephrol. 28 (2008) 723-731
13. Kanmanna V.S., Roh D.D., and Kirschenbaum M.A. Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus. Histol. Histopathol. 13 (1998) 169-179
14. Moorhead J.F., Chan M.K., El-Nahas M., and Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2 (1982) 1309-1311
15. Keane W.F., Kasiske B.L., O'Donnell M.P., and Schmitz P.G. Therapeutic implications of lipid-lowering agents in the progression of renal disease. Am. J. Med. 87 (1989) 21N-24N
16. Cases A., and Colle E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. 99 (2005) S87-S93
17. Ishigaki N., Yamamoto T., Shimizu Y., et al. Involvement of glomerular SREBP-1c in diabetic nephropathy. Biochem. Biophys. Res. Commun. 364 (2007) 502-508
18. Jiang T., Liebman S.E., Lucia S., Li J., and Levi M. Role of altered lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int. 68 (2005) 2608-2620
19. Jiang T., Liebman S.E., Scott Lucia M., Phillips C.L., and Levi M. Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J. Am. Soc. Nephrol. 16 (2005) 2385-2394
20. Proctor G., Jiang T., Iwahashi M., Wang Z., Li J., and Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55 (2006) 2502-2509
21. Sun L., Halaihel N., Zhang W., Rogers T., and Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277 (2002) 18919-18927
22. db/db mice with type 2 diabetes. Diabetes 54 (2002) 2328-2335
23. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
24. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
25. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
26. Ishii S., Iizuka K., Miller B.C., and Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15597-15602
27. Wang W., Sato R., Brown M.S., Hua X., and Goldstein J.L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77 (1994) 53-62
28. Brown M.S., and Goldstein J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. U. S. A. 96 (1996) 11041-11048
29. Jiang T., Wang Z., Proctor G., et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 280 (2005) 32317-32325
30. Kim H.J., and Vaziri N.D. Sterol regulatory element-binding proteins, liver X receptor, ABCA1 transporter, CD36, scavenger receptors A1 and B1 in nephrotic kidney. Am. J. Nephrol. 29 6 (2009) 607-614
31. Barbier O., Torra P., Duguay Y., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726
32. Guan Y., and Breyer M.D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60 (2001) 14-30
33. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15 (2004) 2801-2815
34. Park C.W., Kim H.W., Ko S.H., et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55 (2006) 885-893
35. Mori Y., Hirano T., Nagashima M., Shiraishi Y., Fukui T., and Adachi M. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 56 (2007) 1714-1718
36. Kim H.J., Moradi H., Yuan J., Norris K., and Vaziri N.D. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol., Renal Physiol. 296 (2009) F1297-1306
37. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
38. Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 15 (2004) 659-665
39. th anniversary review. J. Intern. Med. 258 (2005) 94-114
40. Guyton J.R. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr. Opin. Lipidol. 18 (2007) 415-420
41. Ganji S.H., Qin S., Zhang L., Kammana V.S., and Kashyap M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202 1 (2009) 68-75
42. Folch J., Lee M., and Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (2007) 479-509
43. Sakurai H., Hisada Y., Ueno M., Sugiura M., Kawashima K., and Sugita T. Activation of transcription factor NF-κB in experimental glomerulonephritis in rats. Biochim. Biophys. Acta 1316 (1996) 132-138
44. Li D., and Mehta J.L. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1116-1122
45. Li D., and Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101 (2000) 2889-2895
46. Cominacini L., Rigoni A., Pasini A.F., et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J. Biol. Chem. 276 (2001) 13750-13755
47. Cominacini L., Pasini A.F., Garbin U., Davoli A., et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275 (2000) 12633-12638
48. Mehta J.L., Chen J., Hermonat P.L., Romeo F., and Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc. Res. 69 (2006) 36-45
49. Chen M., Masaki T., and Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther. 95 (2002) 89-100
50. Kataoka H., Kume N., Miyamoto S., et al. Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99 (1999) 3110-3117
51. De Winther M., and Hofker M. Scavenging new insights into atherogenesis. J. Clin. Invest. 105 (2000) 1039-1041
52. Febbraio M., and Silverstein R.L. CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 39 (2007) 2012-2030
53. Moore K.J., and Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1702-1711
54. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67 (2004) 411-419
55. Cho K., Kim H., Rodriguez-Iturbe B., and Vaziri N.D. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am. J. Physiol, Renal Physiol. 297 (2009) F106-113
56. Adams C.M., Reitz J., De Brabander J.K., Feramisco J.D., Li L., Brown M.S., and Goldstein J.L. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J. Biol. Chem. 279 (2004) 52772-52780
57. Goldstein J.L., DeBose-Boyd R.A., and Brown M.S. Protein sensors for membrane sterols. Cell 124 (2006) 35-46
58. Bocan T.M., Krause B.R., Rosebury W.S., et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 70-79
59. Storch J., and Thumser A.E. The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta 1486 (2000) 28-44
60. Ganji S.H., Tavintharan S., Zhu D., Xing Y., Kammana V.S., and Kashyap M.L. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res. 45 (2004) 1835-1845
61. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1051-1059
62. Oram J.F., and Vaughan A.M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99 (2006) 1031-1043
63. Tontonoz P., and Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17 (2003) 985-993
64. Laffitte B.A., Repa J.J., Joseph S.B., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 507-512
65. Jiang X.C., Beyer T.P., Li Z., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. J. Biol. Chem. 278 (2003) 49072-49078
66. Vaziri N.D., Deng G., and Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol. Dial. Transplant 14 (1999) 1462-1466
67. Vaziri N.D., Liang K., and Parks J.S. Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int. 59 (2001) 2192-2196
68. Neland T.J., Shw J.T., Jaipuri F.A., et al. Influence of HDL-cholesterol-elevating drugs on he in vitro activity of the HD receptor SR-B1. J. Lipid Res. 48 (2007) 1832-1845
69. Zhang L.H., Kamanna V.S., Zhang M.C., and Kashyap M.L. Niacin inhibit surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid Res. 49 (2008) 1195-1201
70. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin. Am. J. Cardiol. 101 8A (2008) 20B-26B